Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Authors:
- Hannah BowerHBHannah Bower
- Thomas FrisellTFThomas Frisell
- Daniela di GiuseppeDGDaniela di Giuseppe
- Benedicte DelcoigneBDBenedicte Delcoigne
- Ulf LindströmULUlf Lindström
- Carl TuressonCTCarl Turesson
- Katerina ChatzidionysiouKCKaterina Chatzidionysiou
- Elisabet LindqvistELElisabet Lindqvist
- Helena Forsblad-D'ELiaHFHelena Forsblad-D'ELia
- Johan AsklingJAJohan Askling
Open Access
Abstract
Objectives To investigate whether the relative effectiveness of janus kinase inhibitors (JAKis) versus tumour necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs in rheumatoid arthritis differ by the presence or absence of risk factors for cardiovascular (CV) disease, age, sex and smoking. Methods Through Swedish registers, we identified 13 493 individuals with 3166 JAKi, 5575 non-TNFi and 11 286 TNFi treatment initiations 2016–2022. All lines of therapy were included, with the majority in second line or higher. Treatment response was defined as the proportion reaching European Alliance of Associations for Rheumatology (EULAR) good response and Clinical Disease Activity Index (CDAI) remission, respectively, within 6 months. Crude percentage point differences in these proportions (JAKis, and non-TNFis, vs TNFis) overall and by risk factors were observed, and adjusted for confounders using linear regression models. Predicted probabilities of response and remission were estimated from adjusted Poisson models, and presented across CV risk and age. Results Overall, adjusted percentage point differences indicated higher response (+5.0%, 95% CI 2.2% to 7.9%) and remission (+5.8%, 95% CI 3.2% to 8.5%) with JAKis versus TNFis. The adjusted percentage point differences for response in those above 65, at elevated CV risk, and smokers were +5.9% (95% CI 2.7% to 9.0%), +8.3% (95% CI 5.3% to 11.4%) and +6.0% (95% CI 3.3% to 8.7%), respectively. The corresponding estimates for remission were +8.0% (95% CI 5.3% to 10.8%), +5.6% (95% CI 3.0% to 8.2%) and +7.6% (95% CI 5.5% to 9.7%). Conclusions As used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered.Keywords
This publication has 29 references indexed in Scilit:
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled TrialArthritis & Rheumatology, 2019
- Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validationRMD Open, 2018
- Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritisRMD Open, 2017
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialThe Lancet, 2017
- Baricitinib versus Placebo or Adalimumab in Rheumatoid ArthritisNew England Journal of Medicine, 2017
- Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: A Consortium of Rheumatology Researchers of North America Registry StudyArthritis & Rheumatology, 2015
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelinesBMC Medical Research Methodology, 2009
- High ten‐year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population‐based cohort studyArthritis & Rheumatism, 2008
- Multiple imputation of discrete and continuous data by fully conditional specificationStatistical Methods in Medical Research, 2007